Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 2001 Mar;56(3):186–191. doi: 10.1136/thorax.56.3.186

Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects

T Harrison 1, A Wisniewski 1, J Honour 1, A Tattersfield 1
PMCID: PMC1758787  PMID: 11182010

Abstract

BACKGROUND—The potential for long term adverse effects from inhaled corticosteroids relates to their systemic absorption, usually assessed from proxy markers in short term studies. When fluticasone propionate and budesonide have been compared in this way the results have been inconsistent. To determine whether this is because of the subjects studied or the sensitivity of the systemic marker used, we have compared the effects of fluticasone propionate and budesonide in healthy and asthmatic subjects and investigated the effect of treatment on three systemic markers.
METHODS—Forty six healthy subjects were randomised to receive inhaled fluticasone propionate 1500 µg/day (via an Accuhaler), budesonide 1600 µg/day (via a Turbuhaler), or placebo; 31 subjects with moderately severe asthma were randomised to receive the same doses of fluticasone propionate or budesonide but not placebo. Systemic effects in healthy and asthmatic subjects were compared after 7 days. Treatment was continued for another 21 days in the subjects with asthma when systemic effects and asthma control were assessed.
RESULTS—At baseline healthy subjects had higher urinary levels of total cortisol metabolites (TCM) than subjects with asthma. After 7 days of treatment with fluticasone propionate urinary TCM levels in the healthy subjects were significantly lower than in the subjects with asthma (mean difference between groups 1663 µg/day, 95% CI 328 to 2938). This was not the case with budesonide, however, where urinary TCM levels in the healthy subjects remained above those in the asthmatic subjects (mean difference between groups 1210 µg/day, 95% CI -484 to 2904). Urinary TCM levels were considerably more sensitive to the effects of inhaled corticosteroids than morning serum cortisol or osteocalcin concentrations. Only budesonide reduced the serum level of osteocalcin.
CONCLUSIONS—When given by dry powder inhaler for 7 days, fluticasone propionate 1500 µg/day has a greater effect on the hypothalamic-pituitary-adrenal axis in healthy subjects than in subjects with asthma, but this is not the case for budesonide 1600 µg/day. These findings, together with the differences in sensitivity between systemic markers, explain many of the discrepancies in the literature.



Full Text

The Full Text of this article is available as a PDF (157.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ayres J. G., Bateman E. D., Lundbäck B., Harris T. A. High dose fluticasone propionate, 1 mg daily, versus fluticasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. International Study Group. Eur Respir J. 1995 Apr;8(4):579–586. [PubMed] [Google Scholar]
  2. Barnes N. C., Hallett C., Harris T. A. Clinical experience with fluticasone propionate in asthma: a meta-analysis of efficacy and systemic activity compared with budesonide and beclomethasone dipropionate at half the microgram dose or less. Respir Med. 1998 Jan;92(1):95–104. doi: 10.1016/s0954-6111(98)90039-7. [DOI] [PubMed] [Google Scholar]
  3. Barnes N. C., Marone G., Di Maria G. U., Visser S., Utama I., Payne S. L. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group. Eur Respir J. 1993 Jun;6(6):877–885. [PubMed] [Google Scholar]
  4. Barnes P. J., Pedersen S. Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992. Am Rev Respir Dis. 1993 Oct;148(4 Pt 2):S1–26. doi: 10.1164/ajrccm/148.4_Pt_2.S1. [DOI] [PubMed] [Google Scholar]
  5. Boorsma M., Andersson N., Larsson P., Ullman A. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur Respir J. 1996 Jul;9(7):1427–1432. doi: 10.1183/09031936.96.09071427. [DOI] [PubMed] [Google Scholar]
  6. Brutsche M. H., Brutsche I. C., Munawar M., Langley S. J., Masterson C. M., Daley-Yates P. T., Brown R., Custovic A., Woodcock A. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet. 2000 Aug 12;356(9229):556–561. doi: 10.1016/S0140-6736(00)02581-2. [DOI] [PubMed] [Google Scholar]
  7. Clark D. J., Grove A., Cargill R. I., Lipworth B. J. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax. 1996 Mar;51(3):262–266. doi: 10.1136/thx.51.3.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Clark D. J., Lipworth B. J. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax. 1997 Jan;52(1):55–58. doi: 10.1136/thx.52.1.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cumming R. G., Mitchell P., Leeder S. R. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997 Jul 3;337(1):8–14. doi: 10.1056/NEJM199707033370102. [DOI] [PubMed] [Google Scholar]
  10. Donnelly R., Williams K. M., Baker A. B., Badcock C. A., Day R. O., Seale J. P. Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. Am J Respir Crit Care Med. 1997 Dec;156(6):1746–1751. doi: 10.1164/ajrccm.156.6.9703003. [DOI] [PubMed] [Google Scholar]
  11. Fabbri L., Burge P. S., Croonenborgh L., Warlies F., Weeke B., Ciaccia A., Parker C. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax. 1993 Aug;48(8):817–823. doi: 10.1136/thx.48.8.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Faul J. L., Tormey W., Tormey V., Burke C. High dose inhaled corticosteroids and dose dependent loss of diabetic control. BMJ. 1998 Nov 28;317(7171):1491–1491. doi: 10.1136/bmj.317.7171.1491. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Geddes D. M. Inhaled corticosteroids: benefits and risks. Thorax. 1992 Jun;47(6):404–407. doi: 10.1136/thx.47.6.404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Grahnén A., Jansson B., Brundin R. M., Ling-Andersson A., Lönnebo A., Johansson M., Eckernäs S. A. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Eur J Clin Pharmacol. 1997;52(4):261–267. doi: 10.1007/s002280050287. [DOI] [PubMed] [Google Scholar]
  15. Harrison T. W., Oborne J., Wilding P. J., Tattersfield A. E. Randomised placebo controlled trial of beta agonist dose reduction in asthma. Thorax. 1999 Feb;54(2):98–102. doi: 10.1136/thx.54.2.98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hodsman A. B., Toogood J. H., Jennings B., Fraher L. J., Baskerville J. C. Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin. J Clin Endocrinol Metab. 1991 Mar;72(3):530–540. doi: 10.1210/jcem-72-3-530. [DOI] [PubMed] [Google Scholar]
  17. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000 Jul;55(7):603–613. doi: 10.1136/thorax.55.7.603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pauwels R. A., Löfdahl C. G., Laitinen L. A., Schouten J. P., Postma D. S., Pride N. B., Ohlsson S. V. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999 Jun 24;340(25):1948–1953. doi: 10.1056/NEJM199906243402503. [DOI] [PubMed] [Google Scholar]
  19. Priftis K., Milner A. D., Conway E., Honour J. W. Adrenal function in asthma. Arch Dis Child. 1990 Aug;65(8):838–840. doi: 10.1136/adc.65.8.838. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Toogood J. H., Jennings B., Hodsman A. B., Baskerville J., Fraher L. J. Effects of dose and dosing schedule of inhaled budesonide on bone turnover. J Allergy Clin Immunol. 1991 Oct;88(4):572–580. doi: 10.1016/0091-6749(91)90150-m. [DOI] [PubMed] [Google Scholar]
  21. Weiner P., Berar-Yanay N., Davidovich A., Magadle R. Nocturnal cortisol secretion in asthmatic patients after inhalation of fluticasone propionate. Chest. 1999 Oct;116(4):931–934. doi: 10.1378/chest.116.4.931. [DOI] [PubMed] [Google Scholar]
  22. Wilson A. M., Brewster H. J., Lipworth B. J. Dose-response comparison of systemic bioactivity with inhaled budesonide and triamcinolone acetonide in asthmatic adults. J Allergy Clin Immunol. 1998 Nov;102(5):751–756. doi: 10.1016/s0091-6749(98)70014-4. [DOI] [PubMed] [Google Scholar]
  23. Wilson A. M., Lipworth B. J. Short-term dose-response relationships for the relative systemic effects of oral prednisolone and inhaled fluticasone in asthmatic adults. Br J Clin Pharmacol. 1999 Oct;48(4):579–585. doi: 10.1046/j.1365-2125.1999.00058.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Wong C. A., Walsh L. J., Smith C. J., Wisniewski A. F., Lewis S. A., Hubbard R., Cawte S., Green D. J., Pringle M., Tattersfield A. E. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 2000 Apr 22;355(9213):1399–1403. doi: 10.1016/S0140-6736(00)02138-3. [DOI] [PubMed] [Google Scholar]
  25. Yan K., Salome C., Woolcock A. J. Rapid method for measurement of bronchial responsiveness. Thorax. 1983 Oct;38(10):760–765. doi: 10.1136/thx.38.10.760. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES